▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Bukwang Pharmaceutical said on Aug. 7 that it has completed patient enrollment for phase 2b clinical trials of its type 2 diabetes drug candidate MLR-1023. The drug maker said it ex...
[THE INVESTOR] Shares of Korean biotech firm Nature Cell surged over 14 percent on Aug. 6, the first trading day after CEO Ra Jeong-chan was indicted on charges of manipulating the stock price wit...
[THE INVESTOR] Korea’s drug safety watchdog said Monday that it has banned Daebong LS, a local maker of valsartan, from selling and making the active ingredient meant to treat high blood pressure ov...
[THE INVESTOR] Daewoong Pharmaceutical 's self-developed botulinum toxin Nabota is highly expected to receive marketing authorization from the US Food and Drug Administration by February next year ...
[THE INVESTOR] Alteogen said on Aug. 2 that it has received orphan drug designation for ALT-P7, a gastric cancer drug candidate with antibody-drug conjugate, from the US Food and Drug Administratio...
[THE INVESTOR] Korean biopharmaceutical firm Celltrion said on Aug. 2 that its breast cancer biosimilar has been approved by Australia’s regulatory body. The Therapeutic Goods Administration app...
[THE INVESTOR] Prosecutors opened an investigation on Aug. 1 into a financial regulator’s complaint that a pharmaceutical affiliate of Samsung Electronics breached disclosure rules regarding a call ...
[THE INVESTOR] Local analysts dropped Hanmi Pharmaceutical 's share price target on Aug. 1 due to concerns over a weak outlook for the third quarter. A number of equities research analysts issued...
[THE INVESTOR] A US court has ruled in favor of Celltrion in the last chapter of its legal patent battle with Janssen over its version of the US company’s blockbuster drug Remicade. The US District...
[THE INVESTOR] Korea’s biotech firm Alteogen said on July 27 that it has developed a recombinant antibody that can facilitate conversion from intravenous type of protein therapeutics to a more con...
[THE INVESTOR] Korean cosmetics maker Amorepacific saw its second-quarter net profit jump 41.7 percent on-year on July 26, rebounding from last year’s slump sparked by the diplomatic tension between...
[THE INVESTOR] Samsung BioLogics , a contract drug maker, said on July 24 that it has obtained approval from the US Food and Drug Administration to manufacture a finished drug product. This is the...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis posted a whopping US$254 million sales in the European market in the first half of the year, data showed on July 25. According to the co...
[THE INVESTOR] Bukwang Pharmaceutical said on July 24 that its subsidiary Dyna Therapeutics plans to go public on the country’s secondary bourse KOSDAQ next year. Dyna Therapeutics, wholly owned b...
[THE INVESTOR] Korea has high potential to become a major part of the global biopharma business ecosystem with its openness for collaboration and swift clinical trial process, according to executive...
Tinder, not just a dating app in Korea
Sandbox Network aims to go public by 2021
Activist fund to be more involved in Hanjin’s management
Unison Capital inches closer to selling Gong Cha Korea
Money20/20 Asia to include Token Day
Hana Financial kicks off in-house venture projects
Kakao Pay, KT to take part in govt’s Zero Pay
Yanolja hires former Tesla Motors Korea chief
January 23, 2019
